GEN Exclusives

More »

GEN News Highlights

Back to Item »

BMS to Shell Out $2.4B for Medarex

Acquisition gives BMS a stronger position in biologic development, including full rights to a late-stage skin cancer treatment.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Moral Calculations May Shift Biobank Balances

How should consent terms reconcile donors’ moral concerns with biobanks’ research goals?